Rotavirus Vaccine Market Report 2025

This rotavirus vaccine market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The rotavirus vaccine market size has grown rapidly in recent years. It will grow from $9.18 billion in 2024 to $10.14 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to increased awareness of rotavirus, improved healthcare infrastructure, government immunization programs, rising incidence of rotavirus infections, rising birth rates.

The rotavirus vaccine market size is expected to see rapid growth in the next few years. It will grow to $14.96 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to rising birth rates, the expansion of vaccination programs, an increased focus on preventive healthcare, economic growth and improved access, and government policies and funding. Major trends in the forecast period include advancements in vaccine technology, advancements in oral-dosing technologies, improved vaccine formulations, combination vaccines, and digital health integration.

The increasing birth rates are expected to drive the growth of the rotavirus vaccine market in the future. Birth rates, which measure the number of live births per 1,000 people in a given population over a specific period, are influenced by factors such as economic stability, growth, and supportive policies such as parental leave, child benefits, and childcare subsidies. Rotavirus vaccines play a crucial role in reducing severe rotavirus gastroenteritis in infants, leading to improved child health outcomes and lower healthcare costs related to rotavirus infections. For example, according to a January 2023 report by the Centers for Disease Control and Prevention (CDC), the United States experienced a 1% increase in registered births, totaling 3,664,292, compared to the previous year. Consequently, the rise in birth rates is expected to boost the demand for rotavirus vaccines.

Key players in the rotavirus vaccine market are focusing on oral-dosing applicators to improve vaccine delivery efficiency and enhance patient compliance. Oral-dosing applicators are devices designed to administer liquid medications or vaccines directly into the mouth, ensuring accurate dosage and ease of use, especially for infants and young children. For instance, in November 2022, GSK plc, a UK-based pharmaceutical and biotechnology company, received FDA approval for a new oral-dosing applicator-only formulation of ROTARIX (Rotavirus Vaccine, Live, Oral). This formulation is effective against rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) in infants and simplifies vaccine preparation for healthcare providers by removing the need for dose reconstitution.

In June 2024, Murdoch Children's Research Institute, an Australia-based child health research organization, partnered with Incepta Pharmaceuticals Limited. This collaboration aims to enhance protection for children against rotavirus by developing and distributing effective vaccines. The partnership focuses on expanding access to essential rotavirus vaccines in regions with high infection rates and limited healthcare resources. Incepta Pharmaceuticals Limited, a Bangladesh-based pharmaceutical company, is involved in the development of rotavirus vaccines.

Major companies operating in the rotavirus vaccine market are Merck & Co. Inc., Sanofi S.A., Abbott Laboratories, GlaxoSmithKline plc, Daiichi Sankyo Company Limited, Serum Institute of India Private Limited, Sinovac Biotech Ltd., SK Chemicals Co Ltd, Bharat Biotech International Limited, Walvax Biotechnology Co. Ltd., Indian Immunologicals Limited, PT Bio Farma, KFF Inc., Panacea Biotec Limited, Sanyou Biopharmaceuticals Co. Ltd., Inovio Pharmaceuticals Inc., Hilleman Laboratories Private Limited, China National Biotec Group Corporation, Vabiotech, Lanzhou Institute of Biological Products Co. Ltd., Nuvonis Pharmaceuticals Inc., Chengdu Institute of Biological Products Co. Ltd.

North America was the largest region in the rotavirus vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rotavirus vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rotavirus vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rotavirus vaccine is designed to protect against rotavirus infections, which are a common cause of severe diarrhea and gastroenteritis in infants and young children. Administered orally, this vaccine contains live attenuated or inactivated strains of the rotavirus to stimulate an immune response and provide immunity against the virus.

The main types of rotavirus vaccines include rotarix, rotaTeq, rotavac, rotavin-M1, lanzhou lamb, and others. Rotarix is a live attenuated oral vaccine aimed at protecting infants from rotavirus gastroenteritis, which can lead to severe diarrhea and dehydration. The vaccine is used in both pediatric and adult applications, with end users including hospitals, clinics, and academic research institutions.

The rotavirus vaccine market research report is one of a series of new reports that provides rotavirus vaccine market statistics, including rotavirus vaccine industry global market size, regional shares, competitors with an rotavirus vaccine market share, detailed rotavirus vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the rotavirus vaccine industry. This rotavirus vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rotavirus vaccine market consists of sales of combination vaccines, vaccine delivery systems, vaccine doses, and packs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.